PET/CT May Improve Detection of Local CRC Liver Metastasis Progression

The combined imaging approach improved detection of local recurrence and extrahepatic disease during early posttreatment follow‐up for colorectal liver metastases.

By
Andrea Surnit
August 12, 2026
3 min

MDSpire News

At a Glance

Category	Detail
Condition	Colorectal Liver Metastases
Key Mechanisms	Fluorine-18 fluorodeoxyglucose positron emission tomography (F-18 FDG PET) enhances detection of local tumor progression and extrahepatic disease.
Target Population	Patients with colorectal liver metastases treated with thermal ablation or hepatic resection.
Care Setting	Single-center prospective observational cohort study.

Key Highlights

F-18 FDG PET/CT improved detection of local tumor progression compared to CECT alone.
66% of patients showed disease progression at first follow-up.
F-18 FDG PET/CT identified all local tumor progression cases, while CECT detected fewer than half.
CEA levels were unreliable for excluding recurrent disease, with 43% false-negative results.
F-18 FDG PET/CT was more accurate for identifying extrahepatic disease.

Guideline-Based Recommendations

Diagnosis

Use F-18 FDG PET/CT in conjunction with CECT for improved detection of local tumor progression.

Management

Consider multidisciplinary team consensus for diagnosis confirmation.

Monitoring & Follow-up

Monitor CEA serum levels, but be aware of its limitations in detecting disease progression.

Risks

Potential selection bias and reliance on consensus rather than histopathologic confirmation.

Patient & Prescribing Data

Patients undergoing treatment for colorectal liver metastases.

F-18 FDG PET/CT may enhance monitoring post-thermal ablation or liver resection.

Clinical Best Practices

Incorporate F-18 FDG PET/CT into follow-up protocols for colorectal liver metastases.
Utilize a multidisciplinary approach for diagnosis and treatment planning.